Eli Lilly’s weight problems drug now accessible in U.S. pharmacies

Dec 5 (Reuters) – Eli Lilly (LLY.N) stated on Tuesday its not too long ago authorised weight problems therapy Zepbound is now accessible in U.S. pharmacies and will price $550 a month for purchasers whose medical insurance doesn’t cowl the drug, or half the listing value.

Zepbound is the most recent entrant to the fast-growing marketplace for weight-loss medication, which is anticipated to develop to about $100 billion by the top of the last decade.

Wall Road analysts anticipate gross sales of Zepbound to achieve about $2 billion in 2024. Novo Nordisk’s highly effective weight problems drug Wegovy is anticipated to make $7.3 billion in gross sales subsequent 12 months, in accordance with Barclays analyst Emily Discipline.

Each medicines are GLP-1 agonists, a category initially designed to deal with kind 2 diabetes.

Zepbound was added to the U.S. listing of most popular medicines by at the very least one main drug advantages firm, Cigna (CI.N).

Pharmacy profit managers create lists, or formularies, of medicines coated by insurance coverage and reimburse pharmacies for sufferers’ prescriptions.

Lilly stated its business financial savings card program was now accessible at pharmacy chains. Beneath this system, Zepbound might price as little as $25 for sufferers whose insurance coverage covers the drug, and $550 for these whose insurance coverage doesn’t.

The U.S. Meals and Drug Administration authorised Zepbound in November and Lilly stated then it will launch after Thanksgiving.

Zepbound has an inventory value of $1,059.87 a month in contrast with an inventory of $1,349 per-package for Novo’s wildly in style Wegovy.

Lilly’s weight problems drug has the identical energetic ingredient, tirzepatide, as its beforehand authorised diabetes drug Mounjaro, which has been used off-label for weight reduction since its 2022 launch.

Eli Lilly’s shares have surged 60% this 12 months within the run-up to the introduction of Zepbound and the drugmaker has claimed the tenth spot within the listing of the world’s most useful listed corporations by market capitalization.

Our Requirements: The Thomson Reuters Belief Ideas.